Literature DB >> 12948747

N-carbamylglutamate enhances ammonia detoxification in a patient with decompensated methylmalonic aciduria.

Boris Gebhardt1, Stefan Vlaho, Doris Fischer, Adrian Sewell, Hansjosef Böhles.   

Abstract

In patients with methylmalonic aciduria (MMA), the accumulating metabolite propiony-CoA results in an inhibition of the urea circle via the decreased synthesis of N-acetylglutamate, an essential activator of carbamylphosphat synthetase (CPS). This results in one of the major clinical problems which is hyperammonaemia. In a patient with decompensated MMA, the CPS activator carbamylglutamate was tested for its ability to antagonize the propionyl-CoA-induced hyperammonaemia. Oral carbamylgutamate administration resulted in an impressive increase in ammonia detoxification compared to peritoneal dialysis. Safe, fast and easy to administer, carbamylglutamate improves the acute therapy of decompensated MMA by increasing ammonia detoxification and avoiding hyperammonaemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12948747     DOI: 10.1016/s1096-7192(03)00095-7

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  25 in total

1.  Measuring in vivo ureagenesis with stable isotopes.

Authors:  Marc Yudkoff; Nicholas Ah Mew; Yevgeny Daikhin; Oksana Horyn; Ilana Nissim; Itzhak Nissim; Irma Payan; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2010-02-26       Impact factor: 4.797

2.  Acute decompensation of isovaleric acidemia induced by Graves' disease.

Authors:  Antoine Kimmoun; Georges Abboud; Jean Strazeck; Marc Merten; Jean-Louis Guéant; François Feillet
Journal:  Intensive Care Med       Date:  2008-07-08       Impact factor: 17.440

3.  Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidaemia.

Authors:  Bernd C Schwahn; Louisa Pieterse; W Michael Bisset; Peter G Galloway; Peter H Robinson
Journal:  Eur J Pediatr       Date:  2009-08-14       Impact factor: 3.183

4.  Short-term outcome of propionic aciduria treated at presentation with N-carbamylglutamate: a retrospective review of four patients.

Authors:  Sébastien Lévesque; Marie Lambert; Aspasia Karalis; Serge Melancon; Laura Russell; Nancy Braverman
Journal:  JIMD Rep       Date:  2011-09-06

5.  Precision medicine in rare disease: Mechanisms of disparate effects of N-carbamyl-l-glutamate on mutant CPS1 enzymes.

Authors:  Dashuang Shi; Gengxiang Zhao; Nicholas Ah Mew; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2016-12-08       Impact factor: 4.797

6.  Effects of a single dose of N-carbamylglutamate on the rate of ureagenesis.

Authors:  Nicholas Ah Mew; Irma Payan; Yevgeny Daikhin; Ilana Nissim; Itzhak Nissim; Mendel Tuchman; Marc Yudkoff
Journal:  Mol Genet Metab       Date:  2009-07-14       Impact factor: 4.797

7.  N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia.

Authors:  Nicholas Ah Mew; Robert McCarter; Yevgeny Daikhin; Itzhak Nissim; Marc Yudkoff; Mendel Tuchman
Journal:  Pediatrics       Date:  2010-06-21       Impact factor: 7.124

8.  Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia?

Authors:  Virginie Levrat; Isabelle Forest; Alain Fouilhoux; Cécile Acquaviva; Christine Vianey-Saban; Nathalie Guffon
Journal:  Orphanet J Rare Dis       Date:  2008-01-30       Impact factor: 4.123

9.  N-carbamylglutamate for neonatal hyperammonaemia in propionic acidaemia.

Authors:  S Jones; C A B Reed; S Vijay; J H Walter; A A M Morris
Journal:  J Inherit Metab Dis       Date:  2008-02-21       Impact factor: 4.982

10.  N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers.

Authors:  Mendel Tuchman; Ljubica Caldovic; Yevgeny Daikhin; Oksana Horyn; Ilana Nissim; Itzhak Nissim; Mark Korson; Barbara Burton; Marc Yudkoff
Journal:  Pediatr Res       Date:  2008-08       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.